# VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection

> **NCT01241760** · PHASE3 · COMPLETED · sponsor: **Janssen Infectious Diseases BVBA** · enrollment: 744 (actual)

## Conditions studied

- Genotype 1 Chronic Hepatitis C
- Treatment Naive

## Interventions

- **DRUG:** Ribavirin
- **DRUG:** Telaprevir
- **DRUG:** Pegylated interferon alfa-2a
- **DRUG:** Telaprevir

## Key facts

- **NCT ID:** NCT01241760
- **Lead sponsor:** Janssen Infectious Diseases BVBA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2012-08
- **Final completion:** 2012-11
- **Target enrollment:** 744 (ACTUAL)
- **Last updated:** 2014-06-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01241760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01241760, "VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01241760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*